| Item Type | Name |
|
Academic Article
|
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
|
|
Academic Article
|
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
|
|
Academic Article
|
Clinical experience with fludarabine in hemato-oncology.
|
|
Academic Article
|
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
|
|
Concept
|
Vidarabine Phosphate
|
|
Concept
|
Vidarabine
|
|
Academic Article
|
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
|
|
Academic Article
|
Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase.
|
|
Academic Article
|
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
|
|
Academic Article
|
Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.
|
|
Academic Article
|
A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids.
|
|
Academic Article
|
Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production.
|
|
Academic Article
|
Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.
|
|
Academic Article
|
Penetration of mouse fibroblasts by the 5'-phosphate of 9-beta-D-arabinofuranosyladenine and incorporation of the nucleotide into DNA.
|
|
Academic Article
|
Metabolism of 9-beta-D-arabinosyl-2-fluoroadenine-5'-phosphate by mice bearing P388 leukemia.
|
|
Academic Article
|
Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells.
|
|
Academic Article
|
Evolution of the arabinosides and the pharmacology of fludarabine.
|
|
Academic Article
|
Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
|
|
Academic Article
|
Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event.
|
|
Academic Article
|
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
|
|
Academic Article
|
Inhibition of the 3' --> 5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA.
|
|
Academic Article
|
Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro.
|
|
Academic Article
|
Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis.
|
|
Academic Article
|
Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
|
|
Academic Article
|
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
|
|
Academic Article
|
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
|
|
Academic Article
|
Increased toxicity of 9-beta-D-arabinofuranosyladenine in the presence of an inhibitor of adenosine deaminase.
|
|
Academic Article
|
Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo.
|
|
Academic Article
|
The utilization of nucleotides by animal cells.
|
|
Academic Article
|
Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
|
|
Academic Article
|
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
|
|
Academic Article
|
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Cellular retention of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and the pattern of recovery of DNA synthesis in Chinese hamster ovary cells.
|
|
Academic Article
|
9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.
|
|
Academic Article
|
Interaction of arabinosyl nucleotides in K562 human leukemia cells.
|
|
Academic Article
|
Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
|
|
Academic Article
|
Correlation of cytotoxicity with total intracellular exposure to 9-beta-D-arabinofuranosyladenine 5'-triphosphate.
|
|
Academic Article
|
Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388.
|
|
Academic Article
|
Modulation of arabinosylcytosine metabolism during leukemia therapy.
|
|
Academic Article
|
The role of fludarabine in hematological malignancies.
|
|
Academic Article
|
Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias.
|
|
Academic Article
|
Chronic lymphocytic leukemia--correlation of response and survival.
|
|
Academic Article
|
Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
|
|
Academic Article
|
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
|
|
Academic Article
|
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
|
|
Academic Article
|
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
|
|
Academic Article
|
Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation.
|
|
Academic Article
|
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
|
|
Academic Article
|
Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage.
|
|
Academic Article
|
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
|
|
Academic Article
|
Cellular and clinical pharmacology of fludarabine.
|
|
Academic Article
|
Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine.
|
|
Academic Article
|
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
|
|
Academic Article
|
Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
|
|
Academic Article
|
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
|
|
Academic Article
|
Effect of 2'-deoxycoformycin on the biologic half-life of 9-beta-D-arabinofuranosyladenine 5'-triphosphate in CHO cells.
|
|
Academic Article
|
Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
|
|
Academic Article
|
New drugs in the treatment of chronic lymphocytic leukemia.
|
|
Academic Article
|
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
|
|
Academic Article
|
Metabolism and action of purine nucleoside analogs.
|
|
Academic Article
|
Metabolism and action of fludarabine phosphate.
|
|
Academic Article
|
Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism.
|
|
Academic Article
|
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
|
|
Academic Article
|
Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.
|
|
Academic Article
|
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
|
|
Academic Article
|
Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
|
|
Academic Article
|
Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides.
|
|
Academic Article
|
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
|
|
Academic Article
|
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
|
|
Academic Article
|
Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
|
|
Academic Article
|
Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C.
|
|
Academic Article
|
Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues.
|
|
Academic Article
|
Pharmacologically directed ara-C therapy for refractory leukemia.
|
|
Academic Article
|
Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine.
|
|
Academic Article
|
Effect of 2'-deoxycoformycin on the inhibition of deoxyribonucleic acid synthesis by 9-beta-D-arabinofuranosyladenine 5'-triphosphate.
|
|
Academic Article
|
Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia.
|
|
Academic Article
|
2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine.
|
|
Academic Article
|
Fludarabine phosphate: a new active agent in hematologic malignancies.
|
|
Academic Article
|
Clinical experience with fludarabine in leukaemia.
|
|
Academic Article
|
The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo.
|
|
Academic Article
|
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.
|
|
Academic Article
|
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
|
|
Academic Article
|
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
|
|
Academic Article
|
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
|
|
Academic Article
|
Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
|
|
Academic Article
|
Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.
|
|
Academic Article
|
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
|
|
Academic Article
|
Intracellular pharmacodynamics in leukemia therapy.
|
|
Academic Article
|
Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine.
|
|
Academic Article
|
Pharmacology of purine nucleoside analogues.
|
|
Academic Article
|
Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.
|
|
Academic Article
|
Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
|
|
Academic Article
|
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
|
|
Academic Article
|
High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells.
|
|
Academic Article
|
Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes.
|
|
Academic Article
|
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
|
|
Academic Article
|
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
|
|
Academic Article
|
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells.
|
|
Academic Article
|
The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage.
|
|
Academic Article
|
Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine.
|
|
Academic Article
|
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
|
|
Academic Article
|
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
|
|
Academic Article
|
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
|
|
Academic Article
|
A quantitative assay for fragmented DNA in apoptotic cells.
|
|
Academic Article
|
New initiatives with fludarabine monophosphate in hematologic malignancies.
|
|
Academic Article
|
Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation.
|
|
Academic Article
|
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
|
|
Academic Article
|
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
|
|
Academic Article
|
Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
|
|
Academic Article
|
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
|
|
Academic Article
|
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
|
|
Academic Article
|
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
|
|
Academic Article
|
Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
|
|
Academic Article
|
Phase I trial of nelarabine in indolent leukemias.
|
|
Academic Article
|
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.
|
|
Academic Article
|
The expanding role of fludarabine in hematologic malignancies.
|
|
Academic Article
|
Why do drugs work in CLL?
|
|
Academic Article
|
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
|
|
Academic Article
|
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).
|
|
Academic Article
|
Metabolism of 9 β D arabinofuranosyladenine by mouse fibroblasts
|
|
Academic Article
|
Cellular concentrations of dATP and ara-ATP in peripheral blood leukemic cells (PBC) and erythrocytes (RBC) from patients treated with deoxycoformycin (dCF) or arabinosyladenine (ara-A)
|
|
Academic Article
|
The effect of deoxycoformycin (dCF) on the toxicity and metabolism of 9-β-D-arabinofuranosyladenine (ARA-A) and its 5'-triphosphate (ARA-ATP) in CHO cells
|
|
Academic Article
|
Relationship between ARA-ATP concentration, DNA synthetic capacity (DSC) and viability in CHO cells
|
|
Academic Article
|
In vivo cellular kinetics and pharmacology studies of ARA-C and 3-DAU chemotherapy for relapsing adult acute leukemia
|
|
Academic Article
|
Biochemical basis of the increased arabinosyladenine (ARA A) activity in the presence of adenosine deaminase inhibitors (ADI)
|
|
Academic Article
|
Comparison of the metabolism, kinetics, and inhibitory action of arabinosyl-2-fluoroadenine (F-ara-A) and its 5'-monophosphate (F-ara-AMP) in tumor bearing mice
|
|
Academic Article
|
Comparison of the action of 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ARA-A) with 9-β-D-Arabinofuranosyladenine (ARA-A) in CCRF-CEM cells 9-β-Arabinofuranosyladenine (ARA-A) in CCRF-CEM cells
|
|
Academic Article
|
Modulation of vidarabine metabolism by 2'-deoxycoformycin for therapy of acute leukemia
|
|
Academic Article
|
Modulation of arabinosyladenine metabolism by 2'- deoxycoformycin in the therapy of human acute leukaemia
|
|
Academic Article
|
Detection and quantitation of ARA-C 5'-triphosphate (ARA-CTP) in the leukemic cells of adult AML patients treated with ARA-C
|
|
Academic Article
|
Biochemical basis of the therapeutic efficacy of 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A)
|